Vogt-Koyanagi-Harada Syndrome following COVID-19 and ChAdOx1 nCoV-19 (AZD1222) vaccine
Janaína Jamile Ferreira Saraceno, Guilherme Macedo Souza, Luciana Peixoto dos Santos Finamor, Heloísa Nascimento, Rubens Belfort
Abstract
The challenge of COVID-19 has rapidly changed medical management worldwide. The relatively small time from pandemic to vaccines regulatory approval triggered a race toward vaccines development. However, important questions regarding SARS-CoV-2 vaccines remain. A case of complete Vogt-Koyanagi-Harada (VKH) Syndrome that occurred 4 days following SARS-CoV-2 vaccination and another patient that developed VKH 14 days post COVID-19 clinical onset are presented. A causal relationship between COVID-19 and uveitis may exist.
Topics & Concepts
Coronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)PandemicMedicine2019-20 coronavirus outbreakVaccinationVirologyUveitisImmunologyPathologyOutbreakDiseaseInfectious disease (medical specialty)Ocular Diseases and Behçet’s SyndromeRetinal and Optic ConditionsVasculitis and related conditions